Vaccination by Leukemic Apoptotic Corpse Autologous Pulsed Dendritic Cells for AML Patients in First or Second CR
Inclusion Criteria:
- Age between 65-75 years
- Informed consent signed
- Serology HIV, hepatitis B, hepatitis C, HTLV 1 and 2 and Syphilis always negative
(new achievement tests)
- Performance Statut <=2
- Must not be eligible for allogeneic transplantation
- No progressive disease
- Bone marrow and/or peripheral blasts >50% before chemotherapyBlasts >=2.4 10*8
(collected prior to chemotherapy) available No contraindication to cytapheresis
- AML in CR2, except M3-AML
- Patients with refractory AML after induction treatment and a patient eligible for
salvage treatment may allow the production of a first complete remission.
- Patient with newly diagnosed AML with unfavorable cytogenetics and for whom (which) a
course of intensive induction and consolidation treatment for outpatients are
possible
- Patient with newly diagnosed AML with a non-adverse cytogenetics AND either refused
to participate in the protocol GOELAMS LAMS-2007, against the exclusion criteria,
indicating participation in the protocol GOELAMS LAMS-2007 and for whom (which) a
course of induction and intensive outpatient treatment for consolidation are possible
Exclusion Criteria
- Patients who, for reasons psychological, social or geographical boundaries, could be
monitored during the study
- No infections or visceral (cardiac, lung, brain, ...) serious uncontrolled
- History of positive allogeneic bone marrow or solid organ transplantation.
- Previous history of autoimmune disease other than vitiligo
- History of other cancer, except cervical carcinoma in situ or basal cell carcinoma of
the skin unless deemed cured for over 5 years.
- Inability to collect at the diagnosis of relapsed AML, enough leukemic cells (> 2.4
x108)
- Inability to collect during remission, a sufficient number of monocytes in two
leukapheresis maximum
- Failure to obtain a maturation of monocytes
- Patient with AML 3
- Patient may receive an allogeneic hematopoietic stem cell
- No treatment related to treatment of molecules in preclinical development underway or
completed MA within the last 4 weeks